Balazs Halmos: The Biggest Task for Clinicians with New Exciting Data
Balazs Halmos, Associate Director for Clinical Science at Montefiore Einstein Cancer Center, shared a post on X:
“Press release, press release!
OS-imertinib and chemo are making the oncology Jumbotron today- and with a very hot play on OS they have nothing to hide!
With OS being the elephant in the room and both MARIPOSA and FLAURA2 reaching this key endpoint- the pendulum has clearly swung in favor of combos for majority of pts w advanced EGFR+ NSCLC
So which one to favor? Outside of CNS disease where FLAURA2 might be the no-brainer- patient preference/shared decision making might be key
Now w Dato-Dxd also available (+ lets not forget prec onc- MET/4th gen EGFR TKI etc) – for us clinicians the biggest task might be to ensure to use these excellent regimens well/monitor pts carefully to allow each the triple jump of active systemic therapy for best outcome.
More posts featuring Balazs Halmos.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023